
Sanjivani Paranteral Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Nutraceutical market is constantly growing globally, presenting strong demand growth potential.
- Prague JV business expected to stabilize by Q1 FY26, with annual topline of approx. EUR3.5-4 million initially.
- Medium to long-term potential for Prague facility estimated at EUR8-10 million annually by FY27, with scope for expansion.
- HAL facility peak revenue potential around INR 105-110 crores with 19% EBITDA margin; capacity utilization expected to reach 95-100% within a few months of operation.
- Base business sees growth driven by geographic expansion, new product launches (targeting 15-20 launches annually), and increased penetration in existing markets.
- Export-driven growth with current export to domestic sales mix approximately 72:28.
- Industry challenges like supply chain disruptions and freight costs may impact short-term, but overall outlook remains optimistic.
See what Sanjivani Paranteral management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript.
- The company reported existing debt of INR 5 crores and cash equivalents of INR 5.2 crores as of September 2024.
- They have indicated expected capex of around INR 3.5 crores for the base business in FY25 and INR 35-40 crores for the HAL venture in FY25.
- The company seems focused on internal capital allocation and managing working capital efficiently to support growth.
- No direct commentary on raising additional funds through debt or equity was made during the call.
See what Sanjivani Paranteral management said on order book — free account, 30 seconds.
Capex plans
Yes- Capex for the base business was INR 1.46 crores in H1 FY25; expected to be around INR 3.5 crores for FY25 and INR 5.5 crores for FY26.
- HAL venture (IV business) capex expected to be around INR 35-40 crores for FY25.
- New facility in Pune for infusion project is in pipeline and undergoing various approvals; requiring additional capital and technical hires.
- Plant upgrades nearly completed at the Bombay facility; Dehradun facility upgrades to begin soon.
- Potential future expansions in Prague facility targeting EUR 8-10 million revenue with possibility of adding a bigger facility.
- Discussions ongoing for new projects similar to HAL, but details are not disclosed yet due to competitive reasons.
Track Sanjivani Paranteral — get its next earnings analysis in your feed
How does Sanjivani Paranteral rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Sanjivani Paranteral rank in Pharmaceuticals & Biotechnology?
Compare Sanjivani Paranteral against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Sanjivani Paranteral's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem